Rivaroxaban and apixaban as an alternative treatment option to standard therapy (of LMWH) for cancer related VTE treatment.

Overview

About this study

To evaluate the efficacy of rivaroxaban and apixaban in treating malignancy associated VTE by comparing to the standard of care, low molecular weight heparin (LMWH) and compare safety profile (bleeding diathesis) of rivaroxaban and apixaban in patients with malignancy associated VTE and compare it to LMWH treatment.

 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Subject population:

All patients with cancer-associated DVT or PE enrolled into the Mayo Rochester Thrombophilia Clinic Direct Oral Anticoagulants Registry between March 1, 2013 and June 10, 2015 and treated with rivaroxaban, apixaban or LMWH. 

Inclusion Criteria:

  • Diagnosed with an active malignancy at the time of starting DOA or LMWH.
  • Anticoagulation managed by the Mayo Rochester Thrombophilia Clinic.
  • Age 18 – 90 years  

Exclusion Criteria: 

  • Less than 3 months since starting the treatment (rivaroxaban, apixaban or LMWH).
  • Unable to follow up either by mail or telephone at minimum 3 months’ time.  

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Robert McBane, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20305066

Mayo Clinic Footer